Gensun Biomaterials Corporation (Abbreviated as: Gensunbio) was jointly established by Zonhon Biopharma Institute, Inc. (Abbreviated as: Zonhonbio) and an international collaborative R&D team led by national-level experts. Located in the National High-Tech Industrial Development Zone of Changzhou City, Jiangsu Province, it is a national high-tech enterprise in the field of biomedical new materials that integrates synthetic bioengineering technology, a development orientation aligned with new quality productive forces, advanced management and operational models, and a harmonious corporate culture.
Gensunbio owns proprietary R&D and production platforms for synthetic biology-based medical new materials including GSBCOLGEN®, GSBHA®, and GSBELN®; engineering technology platforms for nanobionics and tissue regeneration, GSBM® and GENX® and product application platforms for new biomaterials, GSCOSME® and GSBAiO®. Gensunbio creatively integrates and enhances advanced biotechnologies such as genetic engineering protein recombination technology, ultra-low temperature freeze-drying technology, electrostatic nanofiber spinning technology, physicochemical cross-linking technology of proteins and peptides, and 3D biomaterial printing. This has enabled the development of three major specialty product series in the healthcare sector: the Gensun Medical domain and its medical brand Gensun Yuan®, focusing on bionic repair and tissue regeneration; the Gensun Medical Aesthetics domain and its aesthetic brand Gensun Mei®, focusing on medical aesthetic sculpting and healthcare beauty enhancement; and the Gensun Cosmetics domain and its cosmetics brand GSBAiO®, focusing on functional skincare and wellness nourishment. These efforts have established an integrated upstream-downstream innovation pipeline as its core business, centered on the application development and industrial transformation of synthetic biology-based new materials.
Gensunbio consistently adheres to the philosophy of driving corporate development through distinctive independent innovation and R&D. Its core business innovation pipeline covers innovative regenerative medical products such as nanobionic absorbable repair membranes, collagen-based bionic bone repair materials, plastic surgery regenerative tissue repair patches, bioactive repair membranes, and active biological bone drug-device combinations. This has formed Gensunbio's unique integrated ecosystem spanning innovative raw materials, materials, and products.
The company has filed over 50 invention patents domestically and internationally, with more than 20 patents granted, along with dozens of authorized product trademarks. Customer-centric and committed to excellence, Gensunbio has established a scientific and comprehensive quality management system based on the GB/T19001-2016/ISO9001:2015 standard, which has been certified by an authoritative third-party organization. The certification scope covers the R&D, production, and sales of general liquid-unit skincare products such as toners and gels within the permitted production range. Gensunbio will continue to enhance the influence of its innovative biomedical new materials R&D institution, strive to build an integrated industry-academia-research base with distinctive core technologies, and contribute to the development of new quality productive forces in the field of innovative biomedical new materials and productization for the nation.
